1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome - Pipeline Review, H1 2020, provides an overview of the Sicca Syndrome (Immunology) pipeline landscape.
Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sicca Syndrome (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 4, 1, 12, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Sicca Syndrome (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Immunology).
- The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sicca Syndrome (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sicca Syndrome (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Sicca Syndrome (Sjogren) - Overview
- Sicca Syndrome (Sjogren) - Therapeutics Development
- Sicca Syndrome (Sjogren) - Therapeutics Assessment
- Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
- Sicca Syndrome (Sjogren) - Drug Profiles
- Sicca Syndrome (Sjogren) - Dormant Projects
- Sicca Syndrome (Sjogren) - Discontinued Products
- Sicca Syndrome (Sjogren) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Sicca Syndrome (Sjogren), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Alpine Immune Sciences Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Co, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Cytodyn Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Ibex Biosciences LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Iltoo Pharma, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by ImmunoQure AG, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Kiniksa Pharmaceuticals Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by MeiraGTx Holdings Plc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by MimeTech Srl, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by OSE Immunotherapeutics, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by RemeGen Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Resolve Therapeutics LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Rise Therapeutics LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Rophibio Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharm Co Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by SinoMab Bioscience Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Spectrix Therapeutics LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by TearSolutions LLC, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by Viela Bio Inc, H1 2020
- Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2020
- Sicca Syndrome (Sjogren) - Dormant Projects, H1 2020
- Sicca Syndrome (Sjogren) - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Sicca Syndrome (Sjogren) - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Sicca Syndrome (Sjogren), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alpine Immune Sciences Inc
- Atlantic Bio Sci LLC
- Bristol-Myers Squibb Co
- Cytodyn Inc
- Galapagos NV
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Ibex Biosciences LLC
- Idorsia Pharmaceutical Ltd
- Iltoo Pharma
- ImmunoQure AG
- Immunwork Inc
- Kiniksa Pharmaceuticals Ltd
- MeiraGTx Holdings Plc
- MimeTech Srl
- Novartis AG
- Ono Pharmaceutical Co Ltd
- OSE Immunotherapeutics
- RemeGen Ltd
- Resolve Therapeutics LLC
- Rise Therapeutics LLC
- Rophibio Inc
- Samjin Pharm Co Ltd
- SinoMab Bioscience Ltd
- Spectrix Therapeutics LLC
- Suzhou Sinovent Pharmaceuticals Co Ltd
- TearSolutions LLC
- Viela Bio Inc
- XTL Biopharmaceuticals Ltd
